Cargando…
Parvovirus 4 in Individuals with Severe Hemophilia A and Matched Control Group
Background: Hemophilia is a well-known bleeding disorder with worldwide distribution. Replacement therapy, using plasma-derived or recombinant coagulation factors, comprises a gold standard regimen for the treatment. Regardless of the advancements made in viral inactivation methods in the production...
Autores principales: | Asiyabi, Sanaz, Marashi, Seyed Mahdi, Vahabpour, Rouhollah, Nejati, Ahmad, Azizi-Saraji, Alireza, Mustafa, Aliyeh Sadat, Baghernejad, Asgar, Shoja, Zabiholla, Mansouritorghabeh, Hassan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748245/ https://www.ncbi.nlm.nih.gov/pubmed/35083000 http://dx.doi.org/10.18502/ijhoscr.v15i3.6849 |
Ejemplares similares
-
First Report of Prevalence of Blood-Borne Viruses (HBV, HCV, HIV, HTLV-1 and Parvovirus B19) Among Hemophilia Patients in Afghanistan
por: Mousavi, Sayed Hamid, et al.
Publicado: (2019) -
Human parvovirus B19 and parvovirus 4 among Iranian patients with hemophilia
por: Javanmard, Davod, et al.
Publicado: (2017) -
Clinical and Laboratory Approaches to Hemophilia A
por: Mansouritorghabeh, Hassan
Publicado: (2015) -
Female case with misdiagnosis of hemophilia A who underwent total knee arthroplasty: A case report
por: Bari, Alireza, et al.
Publicado: (2022) -
First detection of human hepegivirus-1 (HHpgV-1) in Iranian patients with hemophilia
por: Bijvand, Yazdan, et al.
Publicado: (2018)